1.
Selected Documents
from the
Opioid Industry
Documents Archive

2.
Title: Imagine the Possibilities Pain Coalition
Date: 2011 October
Collection: National Prescription Opiate Litigation
https://www.industrydocuments.ucsf.edu/drug/docs/ptff0232
Note: Document reflects a presentation at a
meeting between Janssen and the IPPC, a
coalition designed to raise awareness about
undertreated chronic pain by branding chronic
pain as a "public health problem." The
presentation contains evidence that children
as young as elementary school age were
targeted for inclusion within the pain
management campaign.

3.
Title: Affidavit of William T Fannin, MD in Commonwealth of
Kentucky v Purdue Pharma
Date: 2014 July
Collection: Kentucky Opioid Litigation Documents
https://www.industrydocuments.ucsf.edu/drug/docs/qgdf0232

4.
Title: re: Oxy 30
Author: Borelli, Victor; Covidien, Mallinckrodt Pharmaceutical
Date: 2009 January 27
Collection: Washington Post Opioid Collection
https://www.industrydocuments.ucsf.edu/drug/docs/khyc0230
Note: Document reflects an email exchange between
Mallinckrodt sales rep Victor Borelli and a KeySource
Medical distributor joking about widespread addiction to
Oxycontin.

5.
Title: Tapentadol Team Status - Acute Pain Publications
Date: 2009 June 24
Collection: Oklahoma Opioid Litigation Documents
https://www.industrydocuments.ucsf.edu/drug/docs/jlgg0230
Note: Document contains a list of manuscripts regarding Tapentadol
(Nucynta) with possible authors and steps to publication. The document
suggests that the company was providing the outlines and drafts of articles
then seeking MD and PhD co-authors for the manuscripts, raising concerns
regarding ghost-writing.

6.
Title: RE: Conference Call Availability
Author: Dart, Richard; Vorsanger, Gary J; Janssen Scientific
Affairs, LLC; Cicero, Theodore; Washington University
Date: 2012 February 11
Collection: Oklahoma Opioid Litigation Documents
https://www.industrydocuments.ucsf.edu/drug/docs/xhhg0230
Note: Document reflects emails between a healthcare
communications company and authors of a Janssen-funded
study that purported abuse rates of Tapentadol (Nucynta)
were lower than for other opioids.

7.
Title: Insys Trial Transcript - Day 7 in US v Kapoor et al.
Author: United States District Court, District of Massachusetts
Date: 2019 January 29
Collection: Insys Litigation Documents
https://www.industrydocuments.ucsf.edu/drug/docs/pfgf0232
p.108
p.129

8.
Title: KOL Categorization
Author: Thomas, Heather
Date: 2002 February 18
Collection: Oklahoma Opioid Litigation Documents
https://www.industrydocuments.ucsf.edu/drug/docs/lhgg0230
Notes: Email to Janssen Pharmaceuticals employees
describing the company's approach to ‘Key Opinion Leaders’
and the categorization of physicians as "Opponents",
"Neutrals", or "Advocates" for its Duragesic product.

9.
Title: Product Pipeline and Strategy - Very Confidential
Author: Friedman, Michael
Date: 1994 December 29
Collection: Kentucky Opioid Litigation Documents
https://www.industrydocuments.ucsf.edu/drug/docs/fqcf0232

10.
Title: 2006 Objectives for External Affairs Group
Author: Purdue Pharma
Date: 2018 December 20
Collection: Oklahoma Opioid Litigation Documents
https://www.industrydocuments.ucsf.edu/drug/docs/pxgg0230

11.
Title: 2006 Objectives for External Affairs Group
Author: Purdue Pharma
Collection: Oklahoma Opioid Litigation Documents
https://www.industrydocuments.ucsf.edu/drug/docs/pxgg0230

12.
Title: The Epidemic of Pain in America
Author: The American Pain Foundation; Rogers, Mike
Date: 2006 June 13
Collection: Oklahoma Opioid Litigation Documents
https://www.industrydocuments.ucsf.edu/drug/docs/yqgg0230
*A collection of news articles used to brief Congress during a 2006
hearing to raise awareness about an "epidemic" of undertreated
chronic pain in America.
Compiled by the Pain Care Forum, a group of executives from
major pain advocacy groups and pharmaceutical companies, the
materials highlight populations of particular interest to the pain care
industry, including women, veterans, and individuals residing in
minority and low-income communities.

13.
Title: Teva payments to Advocacy Groups
Author: Teva Pharmaceuticals
Date: 2017
Collection: Oklahoma Opioid Litigation Documents
https://www.industrydocuments.ucsf.edu/drug/docs/zrgg0230

14.
Title: 2002 Budget Plan - OxyContin Tablets
Author: Purdue Pharma
Date: 2002
Collection: KHN OxyContin Collection
https://www.industrydocuments.ucsf.edu/drug/docs/pxlh0228

15.
UCSF Industry Documents Library
www.industrydocuments.ucsf.edu
@industrydocs